ADMA Biologics to Present Data at the 2014 Clinical Immunology Society (CIS) Meeting
Business Wire - Thu Apr 03, 6:30AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that its abstract titled "POLYCLONAL HUMAN INTRAVENOUS IMMUNE GLOBULIN (IGIV) WITH HIGH-LEVELS OF RSV NEUTRALIZING ANTIBODIES: A SUMMARY OF ANIMAL AND HUMAN STUDIES" was accepted for a poster presentation during the 2014 Clinical Immunology Society (CIS) meeting.
ADMA Biologics to Present Company Overview at the 13th Annual Needham Healthcare Conference
Business Wire - Mon Mar 31, 6:30AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that Adam Grossman, ADMA's President, Chief Executive Officer and founder, is scheduled to present a company overview at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 8:00 a.m. EDT. The conference will be held from April 8-9, 2014 at The Westin New York Grand Central Hotel, New York, NY.
ADMA Biologics Reports Year End 2013 Results
Business Wire - Fri Mar 28, 6:15AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2013 and provided recent company developments as well as anticipated milestones for 2014.
ADMA Biologics Secures up to $15 Million Loan Commitment from Hercules Technology Growth Capital
Business Wire - Thu Feb 27, 7:00AM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it has secured a loan commitment for up to $15 million from Hercules Technology Growth Capital, Inc. (NYSE:HTGC), a leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets.
ADMA Biologics Expands Plasma Collection Operations of ADMA BioCenters
Business Wire - Mon Feb 03, 3:15PM CST
ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the expansion of its plasma collection operations. ADMA has entered into a new lease for a second collection center and expects to commence construction at this facility during the first half of 2014. Additionally, ADMA has expanded its footprint at its Norcross, Georgia location with additional rented space to grow the donor collection and donor screening areas. This expansion is being conducted to meet an increase in market demand for source plasma.
ADMA Biologics to Present at the Oppenheimer 24th Annual Healthcare Conference
Business Wire - Mon Dec 02, 7:05AM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced it is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference at 1:00 PM ET on December 10, 2013 at the Crowne Plaza Hotel in New York City.
ADMA Biologics Reports Third Quarter 2013 Financial and Operational Results
Business Wire - Tue Nov 12, 5:16PM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported financial and operational results for the third quarter ended September 30, 2013. Third quarter highlights and recent events include the following:
ADMA Biologics Completes Enrollment of Phase III Study for RI-002
Business Wire - Mon Nov 04, 7:03AM CST
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the completion of enrollment for its Phase III clinical study of RI-002. This study is designed to evaluate the efficacy and safety of RI-002 as a novel immune globulin for the treatment of patients who are affected by Primary Immune Deficiency Diseases (PIDD). ADMA expects to have preliminary Phase III data in the fourth quarter of 2014.
RSV Vaccines for the World 2013 Conference Presentation Highlights Data from ADMA Biologics' Human and Animal Study Experience
Business Wire - Tue Oct 29, 7:00AM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases announced today that data from its previous Phase II trial, compassionate use experience and testing in the cotton rat RSV animal model was presented at the 2013 RSV Vaccines for the World Conference (RSVVW). The abstract is titled: "Polyclonal human IVIG with standardized high-levels of RSV neutralizing antibodies: A summary of animal and human studies."
ADMA Biologics, Inc. Announces Closing of Initial Public Offering
Business Wire - Tue Oct 22, 3:15PM CDT
ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. Aggregate net proceeds to ADMA, after deducting underwriting discounts and commissions will be approximately $26.5 million.
ADMA Biologics, Inc. Announces Pricing of Initial Public Offering
Business Wire - Thu Oct 17, 8:11AM CDT
ADMA Biologics, Inc. (OTCQB: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced the pricing of its initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share. All of the shares of common stock are being offered by ADMA Biologics. In addition, ADMA Biologics has granted the underwriters a 30-day option to purchase up to an additional 502,941 shares of common stock at the same price to cover over-allotments, if any. The company's shares are expected to begin trading on The OTCQB Marketplace on October 17, 2013 under the ticker symbol "ADMA."